SCHEDULE 13G/A: Thomas A. Satterfield, Jr. Reports Zero Beneficial Ownership in Edesa Biotech, Inc. Following Significant Share Issuance
Beneficial Ownership Report Amendment
Thomas A. Satterfield, Jr. has filed an amended Schedule 13G indicating zero beneficial ownership of Edesa Biotech, Inc. common stock, primarily due to recent share issuances by the company.
Summary
- Thomas A. Satterfield, Jr. filed an Amendment No. 2 to Schedule 13G concerning his beneficial ownership in Edesa Biotech, Inc.
- The filing reports that Thomas A. Satterfield, Jr. now holds 0% beneficial ownership of Edesa Biotech, Inc.'s common stock.
- This change is attributed to the sale of an additional 3,468,746 shares of common stock by Edesa Biotech, Inc., as reported in its Current Report on Form 8-K filed on February 13, 2025.
- Prior to this, Edesa Biotech, Inc. had 3,467,658 shares of common stock outstanding as of December 11, 2024, as reported in its Annual Report on Form 10-K.
Sentiment
Score: 5
Explanation: The document is a factual report of a change in beneficial ownership due to share issuance. It does not contain explicit positive or negative operational news for the company, though the dilution event itself can be viewed negatively by existing shareholders.
Negatives
- Thomas A. Satterfield, Jr.'s beneficial ownership in Edesa Biotech, Inc. has decreased to 0%, indicating a complete divestment or significant dilution of his stake.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Edesa Biotech, Inc.'s future operations or financial performance.
Industry Context
This filing is a standard disclosure of a change in beneficial ownership, reflecting a specific investor's position rather than broader industry trends. The significant share issuance by Edesa Biotech, Inc. could be part of a capital raising effort, a common activity in the biotech sector for funding research and development.
Stakeholder Impact
- Shareholders, particularly Thomas A. Satterfield, Jr., experienced a significant dilution of their ownership percentage due to the issuance of new shares by Edesa Biotech, Inc.
Key Dates
| Date | Description |
|---|---|
| 12/11/2024 | Date as of which 3,467,658 shares of common stock were outstanding, as reported in Edesa Biotech, Inc.'s Annual Report on Form 10-K. |
| 02/13/2025 | Date of the event requiring the filing of this statement, specifically the sale of an additional 3,468,746 shares of common stock by Edesa Biotech, Inc. |
| 02/18/2025 | Date the Schedule 13G Amendment No. 2 was filed. |
Keywords
Edesa Biotech, Thomas A. Satterfield Jr., Schedule 13G, beneficial ownership, common stock, share dilution, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.